Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy

CONCLUSION: Our results indicate that the combination of chidamide and PD-1 blockade as maintenance therapy could improve the outcomes of aggressive LBCL patients at high risk of failing CAR-T cell therapy.PMID:38615378 | DOI:10.1016/j.intimp.2024.112014

Source: International Immunopharmacology - April 14, 2024 Category: Allergy & Immunology Authors: Zhenhao Wang Hao Xu Yu Mei Min Xiao Yang Cao Liang Huang Zhuming Yang Yicheng Zhang Zhiqiang Han Miao Zheng Zhenya Hong Source Type: research